Gastrointestinal Cancer

The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.

A delay of 10 months or longer between a positive fecal immunochemical test and a follow-up colonoscopy was associated with a higher risk of colorectal cancer.

ASCO updated a 2016 guideline regarding resected pancreatic cancer to include treatment with adjuvant chemotherapy with gemcitabine and capecitabine.

Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma.

Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.

Aspirin had a greater effect on colorectal cancer survival in patients with low-level CD274 (PD-L1) expression in their tumors, according to the results of a study.

Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient.

This video reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.

This video highlights the latest research in carcinoma of the gastroesophageal junction, including how using genetic information can help guide treatment.

Adjuvant chemotherapy is underutilized in elderly patients with stage III colon cancer, despite improved long-term survival after treatment.

Cigarette smoking was associated with an almost 40% reduction in survival among patients with pancreatic cancer.

This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.

Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.

In this interview we discuss the role of genetic testing in patients with colon cancer.

A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.

No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.

In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.

Completing a course of preoperative radiotherapy prior to undergoing surgical resection for rectal cancer was associated with improved survival compared with patients who had an incomplete course of radiotherapy.

This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition.

This video reviews the standard of care for locally advanced anal carcinoma, examines new trials studying novel agents and immunotherapy in the advanced setting, and highlights the need for HPV vaccination for preventing the disease.

Overweight individuals in early adulthood who gained additional weight to become obese later in life are at an increased risk for esophageal and gastric cardia adenocarcinomas.

This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.

The onset of diabetes or the rapid deterioration of existing diabetes may be an early signal for pancreatic cancer for some patients, according to the results of a study presented at the European Cancer Congress.

This video examines the results of a prospective study that looked at associations between survival outcomes and fish and omega-3 fatty acid intake among colon cancer patients.

Young and middle-aged patients diagnosed with colon cancer were more likely to receive postoperative chemotherapy compared with their older-age counterparts, according to the results from a recent cohort study.